The GeV to TeV view of SNR IC443: predictions for Fermi

We present a theoretical model that explains the high energy phenomenology of the neighborhood of SNR IC 443, as observed with the Major Atmospheric Gamma Imaging Cherenkov (MAGIC) telescope and the Energetic Gamma-Ray Experiment Telescope (EGRET). We also discuss how the model can be tested with observations by the Fermi Gamma-ray Large Area Space Telescope. We interpret MAGIC J0616+225 as delayed TeV emission of cosmic-rays diffusing from IC 443 and interacting with a known cloud located at a distance of about 20 pc in the foreground of the remnant. This scenario naturally explains the displacement between EGRET and MAGIC sources, their fluxes, and their spectra. Finally, we predict how this context can be observed by Fermi.Comment: To appear in the Proceedings of the 6th Workshop on Science with the New Generation of High Energy Gamma-Ray Experiments (SciNeGHE '08), held in Padova October 200

Preparations for the public release of high-level CMS data

Volume: 273The CMS Collaboration, in accordance with its commitment to open access and data preservation, is preparing for the public release of up to half of the reconstructed collision data collected in 2010. Efforts at present are focused on the usability of the data in education. The data will be accompanied by example applications tailored for different levels of access, including ready-to-use web-based applications for histogramming or visualising individual collision events and a virtual machine image of the CMS software environment that is compatible with these data. The virtual machine image will contain instructions for using the data with the online applications as well as examples of simple analyses. The novelty of this initiative is two-fold: in terms of open science, it lies in releasing the data in a format that is good for analysis; from an outreach perspective, it is to provide the possibility for people outside CMS to build educational applications using our public data. CMS will rely on services for data preservation and open access being prototyped at CERN with input from CMS and the other LHC experiments.Peer reviewe

MAGIC J0616+225 as delayed TeV emission of cosmic-rays diffusing from SNR IC 443

We present a theoretical model that explains the high energy phenomenology of the neighborhood of SNR IC 443, as observed with the Major Atmospheric Gamma Imaging Cherenkov (MAGIC) telescope and the Energetic Gamma-Ray Experiment Telescope (EGRET). We interpret MAGIC J0616+225 as delayed TeV emission of cosmic-rays diffusing from IC 443 and interacting with a known cloud located at a distance of about 20 pc in the foreground of the remnant. This scenario naturally explains the displacement between EGRET and MAGIC sources, their fluxes, and their spectra. We compare this model with others recently presented, and discuss how it can be tested with observations by the Gamma-ray Large Area Telescope (GLAST).Comment: Accepted for publication in MNRAS Letter

Multi-messenger model for the starburst galaxy M82

In this paper, a consistent model of the multifrequency emission of the starburst galaxy M82, from radio to gamma-rays is presented and discussed. Predictions for observations with Fermi, MAGIC II/VERITAS and CTA telescopes are made. The model is also used to self-consistenty compute the (all flavors) emission of neutrinos resulting from this starburst galaxy, what can be used in considerations of the diffuse contributions of such objects.Comment: Accepted for publication in The Astrophysical Journa

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives. Since the field continues to expand and novel mechanisms that orchestrate multiple cell death pathways are unveiled, we propose an updated classification of cell death subroutines focusing on mechanistic and essential (as opposed to correlative and dispensable) aspects of the process. As we provide molecularly oriented definitions of terms including intrinsic apoptosis, extrinsic apoptosis, mitochondrial permeability transition (MPT)-driven necrosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic cell death, NETotic cell death, lysosome-dependent cell death, autophagy-dependent cell death, immunogenic cell death, cellular senescence, and mitotic catastrophe, we discuss the utility of neologisms that refer to highly specialized instances of these processes. The mission of the NCCD is to provide a widely accepted nomenclature on cell death in support of the continued development of the field

Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two earlier end points, proposed in the setting of first-line chemo-/immunotherapy, as surrogates for OSprogression-free survival (PFS) status at 24months (PFS24) and complete response at 30months (CR30) post-ASCT. We also have investigated the clinical features of patients with early progression after ASCT. Data were available for 626 chemosensitive FL patients who received ASCT between 1989 and 2007. Median follow-up was 12.2years from ASCT. In the PFS24 analysis, 153 (24%) patients progressed within 24months and 447 were alive and progression-free at 24months post-ASCT (26 who died without disease progressions within 24months were excluded). Early progression was associated with shorter OS (hazard ratio [HR], 6.8; P=0.00001). In the subgroup of patients who received an ASCT in the setting or relapse after being exposed to rituximab, the HR was 11.3 (95% CI, 3.9-30.2; P<0.00001). In the CR30 analysis, 183 of 596 (31%) response-evaluable patients progressed/died with 30months post-ASCT. The absence of CR30 was associated with shorter OS (HR, 7.8; P<0.00001), including in patients with prior rituximab (HR, 8.2). PFS24 and CR30 post-ASCT are associated with poor outcomes and should be primary end points. Further research is needed to identify this population to be offered alternative treatments